explore -WSS

explore

author：comprehensive 2025-10-01 01:50:30 - browse：44

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： DeSantis says Trump could've 'come out more forcefully' during Jan. 6

knowledge

WSS

Allen Institute goes after foundational questions, CEO Costa says

In shift, Texas to cover initial consult for Afghan baby's gene therapy

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

More hospitals are billing patients as online messages surge

A look at other Americans who have crossed into North Korea over the years

Stories you might have missed in 2023: health, science, medicine

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Psychedelics group wrestles with new pharma identity

15 die by electrocution after transformer explodes in northern India

Tori Bowie and the unacceptable rates of Black maternal death

A look at other Americans who have crossed into North Korea over the years

The high cost of giving birth even with insurance

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Trump demands the U.S. pay no more for drugs than other countries … again

Merck to acquire Harpoon Therapeutics for $680 million

Virginia high school admissions case could be legal follow

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

leisure time

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

A Theranos scientist

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Study suggests new cause of Down syndrome: cells linked to aging

Wikipedia

leisure time

knowledge

focus